Navigation Links
Long-Term Data Show Advantages for TAXUS® Liberte® Stent in Small Vessels and Long Lesions
Date:9/22/2010

NATICK, Mass., Sept. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.  Five-year results from the TAXUS ATLAS trial and four-year results from the TAXUS ATLAS Small Vessel and Long Lesion trials continue to show significant advantages for the thin-strut TAXUS Liberte Stent when compared to the first-generation TAXUS® Express® Stent.  Analysis of the data was presented by the Co-Principal Investigators of the TAXUS ATLAS trials, Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and John A. Ormiston, M.D., Mercy Angiography Unit, Mercy Hospital, Auckland, New Zealand, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.  

"The TAXUS ATLAS trials continue to reinforce the long-term safety and efficacy of the TAXUS Liberte Stent in a variety of complex lesions," said Dr. Turco.  "The data showed sustained positive outcomes in workhorse lesions, significantly reduced rates of re-intervention in small vessels and important safety differences in long lesions.  The ATLAS data suggest that improvements in stent design and a reduction in strut thickness may contribute to improved clinical outcomes for patients treated with the TAXUS Liberte Stent."

TAXUS ATLAS "Workhorse" LesionsData from 871 patients in the TAXUS ATLAS trial demonstrated that the durable safety and efficacy profile of the TAXUS Liberte Stent is maintained at five years in de novo coronary ("workhorse") lesions.  In spite of more complex patients treated with the TAX
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Research Solutions, Inc. (OTCQB: ... and medical (STM) information for life science companies, academic ... to present at the LD Micro Invitational being held ... in Los Angeles . ... on Wednesday, June 3rd at 9:30 a.m. Pacific time, ...
(Date:6/1/2015)...  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... ,nal-IRI, in a Phase 1 investigator-sponsored study at the ... were presented at the 2015 American Society of Clinical ... Results from this study show a tolerable ... when given intravenously.  Based in part on ...
(Date:6/1/2015)... 2015 About Pressure Relief ... area and improve the quality life of patients who ... play a significant role in inhibiting the growth and ... to turn or rotate an immobile patient by providing ... overlay, and specialty beds. These devices have the ability ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
... , SAN DIEGO, Oct. 6 NuVasive, Inc. (Nasdaq: ... for minimally disruptive surgical treatments for the spine, announced details ... will take place on Tuesday, October 20, 2009, after the ... conference call on Tuesday, October 20, 2009, at 5:30 p.m. ...
... 6 Physiotherapy Associates, the nation,s foremost provider ... free educational brochure on the benefits of physical ... Physical Therapy Month," as designated by the American ... offers Physiotherapy Associates, 1,500 clinicians a way to ...
Cached Medicine Technology:NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 2NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 3Physiotherapy Associates Marks 'National Physical Therapy Month' With Free Educational Brochure 2
(Date:6/2/2015)... ODU , a worldwide ... solutions and cable assemblies, is announcing its highly ... US market. , ODU MINI-SNAP® is ... self- securing circular connector solution is ideal for ... significant customization such as: sensor devices, data collecting ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 The Non-GMO Project offers ... made according to rigorous best practices for GMO ... in compliance with the Non-GMO Project Standard - ... ingredients, facility inspections and an annual audit to ... , “Savoury Systems is and has always been ...
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity inspired ... fashion cocktail dresses. The company carries more than 1000 ... suitable for a wide variety of summer events like ... make high quality trendy special occasion dresses ... satin, chiffon and cotton. Their products feature a wide ...
(Date:6/2/2015)... 02, 2015 TranSlice: Reveal from Pixel Film ... TranSlice: Reveal allows Final Cut Pro X users to transition ... reveal their next screen. , TranSlice Reveal brings back the ... Cut Pro X users can now transition from one ... With every panel orientation and direction covered, no transition will ...
Breaking Medicine News(10 mins):Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2
... Senator Norm Coleman, Deputy HHS Secretary Tevi ... patient and medical community participate in a conference to, ... Preventive, Services Task Force report dismissing the vital role ... The Potomac,Institute for Policy Studies and the Glaucoma Foundation ...
... Although all cancers are not alike, most share common ... mutation or faulty biochemical signaling pathway. For that reason, ... impact on many others. Increasingly, researchers are discovering ways ... broadening the targets of already-approved targeted therapeutics. ...
... for more accurately determining the composition of medicines. ... techniques that were previously considered to be incompatible: ... detection technique mass spectroscopy (MS). He has used ... mechanism for the active ingredient and excipients in ...
... fool Mother Nature, experts say , , WEDNESDAY, Oct. 24 (HealthDay ... an hour more of sunlight, but it appears that their ... researchers report. , In fact, daylight savings time can cause ... our bodies, according to the report in the Oct. 24 ...
... Oct. 24 In a pioneering effort, Children,s,Hospital ... Pittsburgh School of,Medicine have joined forces to launch ... field of pediatric research. The potential of ... Mellon Foundation through a groundbreaking gift of $23 ...
... of ... ARLINGTON, Va., Oct. 24 Vangent, Inc., a leading,provider ... leading expert in governmental healthcare programs and member,eligibility, today ... services to redeem members who recently received letters,from the ...
Cached Medicine News:Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 2Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 3Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 4Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 6Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 7Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 8Health News:New technique improves purity of medicines 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 3Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 2Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 2Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 4
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: